Bloomberg
All-or-Nothing Biotech Bets Dented by Rising Treasury Yields
Thursday, October 22, 2026
Biotechnology stock valuations have declined as U.S. Treasury yields increased. Investors typically view biotech companies as higher-risk investments due to their dependence on uncertain drug development outcomes. Rising yields make bonds and other fixed-income securities more attractive relative to volatile equities, which can reduce capital flowing to speculative stocks.
Original reporting:
